The ROE as of November 2024 (TTM) for UroGen Pharma Ltd. (URGN) is 932.03%

According to UroGen Pharma Ltd.’s latest financial reports and current stock price. The company's current ROE is 932.03%. This represents a change of -4611.77% compared to the average of -20.66% of the last 4 quarters.

UroGen Pharma Ltd. (URGN) Historical ROE (quarterly & annually)

How has URGN ROE performed in the past?

The mean historical ROE of UroGen Pharma Ltd. over the last ten years is -156.10%. The current 932.03% ROE has changed -697.09% with respect to the historical average. Over the past ten years (40 quarters), URGN's ROE was at its highest in in the March 2022 quarter at 166.29%. The ROE was at its lowest in in the December 2021 quarter at -338.19%.

UroGen Pharma Ltd. (URGN) ROE by Quarter and Year

Discovering the peaks and valleys of UroGen Pharma Ltd. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

UroGen Pharma Ltd. (URGN) Average ROE

How has URGN ROE performed in the past?

The current ROE of UroGen Pharma Ltd. (URGN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

UroGen Pharma Ltd. (URGN) ROE vs. Peers

How is URGN’s ROE compared to its peers?

UroGen Pharma Ltd.’s ROE is greater than Eliem Therapeutics, Inc. (-47.03%), less than Inhibrx Biosciences, Inc. (1.45%), greater than Merrimack Pharmaceuticals, Inc. (-35.28%), greater than Celcuity Inc. (-62.66%), greater than Enliven Therapeutics, Inc. (-29.46%), greater than Ikena Oncology, Inc. (-39.59%), greater than Xilio Therapeutics, Inc. (-214.74%), greater than Protara Therapeutics, Inc. (-55.96%), greater than Scholar Rock Holding Corporation (-145.60%), greater than Vaccitech plc (-18.36%), greater than Generation Bio Co. (-104.85%), greater than Kronos Bio, Inc. (-64.55%), greater than Erasca, Inc. (-42.26%), greater than C4 Therapeutics, Inc. (-42.45%), greater than Edgewise Therapeutics, Inc. (-26.83%), greater than Ovid Therapeutics Inc. (-39.24%), greater than Connect Biopharma Holdings Limited (7.21%), greater than PepGen Inc. (-60.17%), greater than Tyra Biosciences, Inc. (-25.14%), greater than Compass Therapeutics, Inc. (-28.67%), greater than Vigil Neuroscience, Inc. (-83.89%), greater than PureTech Health plc (-26.28%),

Build a custom stock screener for UroGen Pharma Ltd. (URGN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like UroGen Pharma Ltd. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

UroGen Pharma Ltd. (URGN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like UroGen Pharma Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.